$143.37
Value $354B
MRK and NRC stock compared: price, dividend, valuation and results, from SEC filings.
$143.37
Value $354B
$25.89
Value $549M
Merck & Company (MRK) has a market value of $354B and NRC Health (NRC) $549M. Over the last year, with dividends, MRK moved +58.8% and NRC +75.8%. The P/E is 144.5 for MRK and 89.6 for NRC. Dividend yield: MRK 2.37%, NRC 2.47%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
MRK$354B
NRC$549M
MRK is 645 times NRC
Revenue, 12 months
MRK$67.4B
NRC$144M
MRK is 469 times NRC
Net income, 12 months
MRK$2.5B
NRC$6.1M
MRK is 400 times NRC
Operating margin
MRK–
NRC11.1%
ROIC
MRK3.9%
NRC10.4%
6.5 points apart
P/E
MRK144.5
NRC89.6
MRK is 1.6 times NRC
Dividend yield
MRK2.4%
NRC2.5%
0.1 points apart
5-year return
MRK+98.6%
NRC-35.3%
133.9 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
MRK+98.6%
NRC-35.3%
| Period | MRKWith dividends | NRCWith dividends |
|---|---|---|
| 1 year since November 14, 2025 | +58.8%Price +54.3% | +75.8%Price +70.0% |
| 3 years since November 17, 2023 | +54.4%+15.6% a yearPrice +40.9% | -31.9%-12.0% a yearPrice -37.3% |
| 5 years since November 16, 2021 | +98.6%+14.7% a yearPrice +70.5% | -35.3%-8.3% a yearPrice -43.6% |
| 10 years since November 18, 2016 | +229.5%+12.7% a yearPrice +142.8% | +100.4%+7.2% a yearPrice +61.8% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
MRKMerck & CompanyNRCNRC Health
| Price | $143.37 | $25.89 |
|---|---|---|
| Market value | $354B | $549M |
| Enterprise value (EV) | $399B | $649M |
| P/E | 144.5 | 89.6 |
| P/E, 5-year median | 14.8 | 28.4 |
| P/B | 7.9 | – |
| EV/EBIT | 83.7 | 40.8 |
| Free cash flow yield | 4.2% | 3.4% |
| Revenue, 12 months | $67.4B | $144M |
|---|---|---|
| Net income, 12 months | $2.5B | $6.1M |
| Free cash flow, 12 months | $14.7B | $18M |
| Earnings per share, 12 months | $0.98 | $0.27 |
| Revenue growth, year on year | 1.3% | -4.0% |
| Revenue growth a year, past | +9.4%over 5 years | +0.6%over 5 years |
| EPS growth a year, past | +21.2%over 5 years | +103.0%over 5 years |
| Gross margin | 71.8% | – |
|---|---|---|
| Operating margin | – | 11.1% |
| Net margin | 3.6% | 4.3% |
| ROIC | 3.9% | 10.4% |
| ROE | 5.2% | 78.2% |
| Cash | $9.7B | $3.6M |
|---|---|---|
| Total debt | $53.8B | $103M |
| Net debt / EBITDA | 5.7 | 4.2 |
| Interest cover | 2.4× | 2.9× |
| Dividend yield | 2.4% | 2.5% |
|---|---|---|
| Dividend per share, 12 months | $3.40 | $0.64 |
| Dividend growth a year, past | +5.8%over 5 years | – |
| Buyback yield | 1.4% | 3.7% |
| Shareholder yield | 3.8% | 6.1% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Merck & Company ($354B) is about 645.3 times NRC Health ($549M), at today's prices.
Since November 18, 2016, MRK's price moved +142.8% and NRC's +61.8%. With dividends: MRK +229.5% (+12.7% a year), NRC +100.4% (+7.2% a year). Past returns do not predict future ones.
The dividend yield at today's price is 2.37% for Merck & Company and 2.47% for NRC Health. Over the last twelve months they paid $3.40 and $0.64 per share.
At today's price, the P/E is 144.5 for MRK and 89.6 for NRC. The median of the last five years was 14.8 and 28.4, which shows where each stands against its own past.
Over the last twelve months, the net margin was 3.6% for Merck & Company and 4.3% for NRC Health, and the operating margin – and 11.1%. Revenue was $67.4B and $144M.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.